Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
तुलना करने के लिए मीट्रिक्स | 4503 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4503पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 50.0x | 13.7x | −0.6x | |
PEG अनुपात | 1.12 | −0.17 | 0.00 | |
क़ीमत/बुक | 1.8x | 1.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 1.5x | 1.6x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 30.8% | 14.1% | 55.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 21.9% | 9.2% | अनलॉक करें |